Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international,

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.

Volume 370, Issue 9586, Pages (August 2007)

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist.

Volume 386, Issue 10006, Pages (November 2015)

Volume 381, Issue 9872, Pages (March 2013)

Volume 149, Issue 5, Pages (May 2016)

Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of.

Volume 355, Issue 9212, Pages (April 2000)

Volume 379, Issue 9824, Pages (April 2012)

Volume 380, Issue 9846, Pages (September 2012)

Volume 357, Issue 9273, Pages (June 2001)

Volume 136, Issue 4, Pages (October 2015)

Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled.

Volume 349, Issue 9057, Pages (April 1997)

Volume 12, Issue 11, Pages (October 2011)

Volume 376, Issue 9747, Pages (October 2010)

Volume 8, Issue 10, Pages (October 2009)

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised,

Volume 11, Issue 4, Pages (April 2012)

Volume 376, Issue 9734, Pages (July 2010)

Volume 373, Issue 9679, Pages (June 2009)

Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer Russell D. Hull, MBBS, MSc, Graham F. Pineo,

Demographic and practice factors predicting repeated non-attendance in primary care: a national retrospective cohort analysis David A Ellis, PhD, Ross.

Paul D. Stein, MD, Russell D. Hull, MBBS, MSc, Fadi Matta, MD, Abdo Y

Volume 389, Issue 10076, Pages (April 2017)

Evaluation of early administration of simvastatin in the prevention and treatment of delirium in critically ill patients undergoing mechanical ventilation.

Volume 376, Issue 9734, Pages (July 2010)

Volume 9, Issue 5, Pages (May 2008)

New Oral Anticoagulants and VTE Management

Volume 392, Issue 10145, Pages (August 2018)

Venous Thromboembolism with Chronic Liver Disease

Volume 385, Issue 9967, Pages (February 2015)

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

Volume 12, Issue 9, Pages (September 2013)

Volume 373, Issue 9677, Pages (May 2009)

Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer Russell D. Hull, MBBS, MSc, Graham F. Pineo,

Deep venous thrombosis after repair of nonruptured abdominal aneurysm

Volume 373, Issue 9663, Pages (February 2009)

Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants Matthew R.

Anticoagulation and Thrombosis Management

Volume 373, Issue 9679, Pages (June 2009)

Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled.

Lifetime Risk of Venous Thromboembolism in Two Cohort Studies

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised,

Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study Sune F Nielsen, PhD, Prof Børge G Nordestgaard,

Maternal pre-pregnancy infection with hepatitis B virus and the risk of preterm birth: a population-based cohort study Jue Liu, PhD, Shikun Zhang, MD,

A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts Prof.

Volume 379, Issue 9812, Pages (January 2012)

Volume 12, Issue 6, Pages (June 2013)

Volume 15, Issue 1, Pages (January 2014)

Adrian Martineau The Lancet Respiratory Medicine

Volume 375, Issue 9709, Pages (January 2010)

Volume 392, Issue 10144, Pages (July 2018)

Volume 371, Issue 9627, Pages (May 2008)

Volume 378, Issue 9786, Pages (July 2011)

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

Volume 375, Issue 9726, Pages (May 2010)

Volume 373, Issue 9658, Pages (January 2009)

Volume 375, Issue 9719, Pages (March 2010)

Prof GJB van Ommen, PhD, E Bakker, PhD, JT den Dunnen, PhD The Lancet

Volume 375, Issue 9714, Pages (February 2010)

Volume 361, Issue 9352, Pages (January 2003)

Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin.

Volume 376, Issue 9747, Pages (October 2010)

Volume 12, Issue 1, Pages (January 2011)

Clive Kearon, Michael J Kovacs, Jim A Julian

Volume 388, Issue 10042, Pages (July 2016)

Pleurodesis for primary spontaneous pneumothorax – Authors' reply

Deep venous thrombosis after repair of nonruptured abdominal aneurysm

Presentation transcript:

Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study Dr Walter Ageno, MD, Lorenzo G Mantovani, DSc, Prof Sylvia Haas, MD, Prof Reinhold Kreutz, MD, Danja Monje, Dipl Biol, Jonas Schneider, MD, Martin van Eickels, MD, Martin Gebel, PhD, Elizabeth Zell, MStat, Prof Alexander G G Turpie, MD The Lancet Haematology Volume 3, Issue 1, Pages e12-e21 (January 2016) DOI: 10.1016/S2352-3026(15)00257-4 Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile *Early switchers were defined as patients for whom rivaroxaban was planned, but who initially received heparin or fondaparinux for at least 2–14 days, a vitamin K antagonist for 1–14 days, or both before switching to rivaroxaban. 116 patients in the rivaroxaban group and 128 in the standard anticoagulation group were lost to follow-up (see appendix p 8). The Lancet Haematology 2016 3, e12-e21DOI: (10.1016/S2352-3026(15)00257-4) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 2 Cumulative incidences of the primary safety and effectiveness endpoints in the safety population (A) Major bleeding. (B) Recurrent VTE. (C) All-cause mortality. HR=hazard ratio. VTE=venous thromboembolism. The Lancet Haematology 2016 3, e12-e21DOI: (10.1016/S2352-3026(15)00257-4) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 3 Relative safety and effectiveness of rivaroxaban and standard anticoagulation for selected patient subgroups in the propensity score-adjusted population (A) Major bleeding. (B) Recurrent venous thromboembolism.*Some demographic parameters have data missing. †HR could not be calculated because of small number of events. HR=hazard ratio. CrCl=creatinine clearance. The Lancet Haematology 2016 3, e12-e21DOI: (10.1016/S2352-3026(15)00257-4) Copyright © 2016 Elsevier Ltd Terms and Conditions